DISTRUTTI, ELEONORA
 Distribuzione geografica
Continente #
NA - Nord America 2.052
EU - Europa 1.416
AS - Asia 479
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.952
Nazione #
US - Stati Uniti d'America 2.048
IE - Irlanda 422
IT - Italia 322
HK - Hong Kong 200
UA - Ucraina 195
VN - Vietnam 148
FR - Francia 85
SE - Svezia 78
CN - Cina 72
RU - Federazione Russa 68
FI - Finlandia 67
DE - Germania 66
TR - Turchia 37
GB - Regno Unito 26
CH - Svizzera 20
RO - Romania 18
BE - Belgio 15
NL - Olanda 11
AT - Austria 9
UZ - Uzbekistan 8
SG - Singapore 6
LB - Libano 5
CA - Canada 3
GR - Grecia 3
PL - Polonia 3
AL - Albania 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
EU - Europa 2
JP - Giappone 2
EE - Estonia 1
ES - Italia 1
HU - Ungheria 1
KR - Corea 1
MA - Marocco 1
MX - Messico 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.952
Città #
Chandler 569
Dublin 417
San Mateo 214
Hong Kong 200
Dong Ket 148
Perugia 119
Altamura 104
Medford 101
Princeton 100
Jacksonville 94
Ann Arbor 87
Lawrence 84
Wilmington 83
Andover 62
Beijing 53
Izmir 37
Ashburn 30
Saint Petersburg 29
Des Moines 21
Timisoara 18
Boardman 15
Brussels 15
Falls Church 14
Redwood City 14
Houston 13
Redmond 12
Den Haag 11
Helsinki 11
Norwalk 11
San Paolo di Civitate 11
Woodbridge 10
Vienna 7
Brugg 6
Florence 6
Dearborn 5
Cambridge 4
Chicago 4
Lappeenranta 4
New York 4
Shanghai 4
Auburn Hills 3
Fremont 3
Giugliano In Campania 3
Lausanne 3
Prata Di Pordenone 3
San Diego 3
Singapore 3
Toronto 3
Abidjan 2
Bologna 2
Cincinnati 2
Esslingen am Neckar 2
Ferrara 2
Kiev 2
London 2
Menlo Park 2
Moscow 2
Nanjing 2
Naples 2
Philadelphia 2
Radeberg 2
Rome 2
Seattle 2
Stroncone 2
Tokyo 2
Alameda 1
Avignon 1
Bastia umbra 1
Bisaccia 1
Boydton 1
Bratislava 1
Budapest 1
Castiglione del Lago 1
Catania 1
Chengdu 1
Cork 1
Cormeilles-en-Parisis 1
Deruta 1
Edinburgh 1
Foligno 1
Frankfurt am Main 1
Guangzhou 1
Gwangmyeong 1
Hanover 1
Hefei 1
Iglesias 1
Jinan 1
Landshut 1
Lexington 1
Lit 1
Ludwigshafen 1
Magdeburg 1
Mexico 1
Miami 1
Moline 1
Napoli 1
Palermo 1
Phoenix 1
Prague 1
Rabat 1
Totale 2.844
Nome #
Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. 80
Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice. 80
Anti-HIV Protease Inhibitors Interact With NSAIDs and Exacerbate Small Intestine Enteropathy Induced by NSAIDs 79
The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines 76
The aryl hydrocarbon receptor (AhR) mediates the counter-regulatory effects of pelargonidins in models of inflammation and metabolic dysfunctions 69
A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. 66
Antiatherosclerotic effect of farnesoid X receptor. 66
Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition 65
BAR501, A SELECTIVE GPBAR1 AGONIST, PROMOTES ADIPOSE TISSUE BROWNING AND AUTOPHAGY AND IMPROVES LIPID METABOLISM AND STEATO-HEPATITIS IN MICE FEED A HIGH FAT DIET 65
Effect of bombesin on pancreatic regeneration after subtotal distal pancreasectomy. 61
Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. 60
a Farnesoid-X-Receptor (FXR)-Glucocorticoid Receptor (GR) Cascade Regulates Intestinal Innate Immunity in Response to FXR Activation 56
Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. 56
Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis 54
A Comprehensive Analysis of Small Heterodimer Partner (SHP) Target Genes in Hepatic Stellate Cells and the Discovery of a New Class of SHP Agonists That Reduces Liver Fibrosis 54
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies 53
Identification of Cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1 53
I peptidil leucotrieni regolano la secrezione di pepsinogeno e la mobilitazione del calcio nelle cellule principali isolate 52
Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential 52
Sa1518 – Mechanism of Acute Liver Decompensation Caused by Obeticholic Acid in Cholestasis is Fxr Dependent 51
Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. 50
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. 50
FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. 49
241 - GPBAR1 (TGR5) is a Modulator of Liver Immunity and Reverses Liver Inflammation in a Mouse Models of Acute Hepatitis 49
The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. 48
Farnesoid X receptor suppresses constitutive androstane receptoractivity at the multidrug resistance protein-4 promoter. 48
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. 48
Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatorybowel diseases and arthritis 48
The third gas: H2S regulates perfusion pressure in both theisolated and perfused normal rat liver and in cirrhosis. 47
Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases 47
Su1053 - Bar704, a Potent and Selective Fxr Agonist Protects Against Intestinal Fibrosis 47
DISCOVERY OF BAR704, A POTENT AND SELECTIVE FXR AGONIST, THAT PROTECTS AGAINST LIVER FIBROSIS 47
Tu1546 – Gpbar1 is a Modulator of Liver Immunity and Its Agonism Reverses Acetaminophen-Induced Hepatotoxicity by Modulating Recruitment of Liver Macrophages 47
Counter-regulatory role of bile acid activated receptors in immunity andinflammation. 46
Mo2014 – Comparative Effects of Bar502, a Dual Fxr and Gpbar1 Agonist, Obeticholic Acid and Ursodeoxycholic Acid in a Rodent Model of Nash 46
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. 45
Inhibition of NF-κB by a PXR-dependent pathwaymediates counter-regulatory activities of rifaximin on innate immunity inintestinal epithelial cells. 43
Tu1738 - The Aryl Hydrocarbon Receptor Mediates Anti-Inflammatory Activities of Natural and Synthetic Pelargonidines in Mouse Models of Colitis 43
The Pharmacology of Bile Acids and Their Receptors 43
Serum Bile Acid Levels Before and After Sleeve Gastrectomy and Their Correlation with Obesity-Related Comorbidities 43
The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate 42
Metabolic variability of a multispecies probiotic preparation impacts on the anti-inflammatory activity 42
Nitric oxide-releasing NSAIDs inhibit interleukin 1beta converting enzyme-like cysteine proteases and protect endothelial cells from appopthosis induced by TNFx 42
The Bile Acid Receptor GPBAR1 Modulates CCL2/CCR2 Signaling at the Liver Sinusoidal/Macrophage Interface and Reverses Acetaminophen-Induced Liver Toxicity 42
The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. 41
Bile Acids Activated Receptors Regulate innate immunity 41
The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. 40
The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. 38
Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH 38
SHP-dependent and -independent induction of peroxisomeproliferator-activated receptor-γ by the bile acid sensor farnesoid X receptorcounter-regulates the pro-inflammatory phenotype of liver myofibroblasts. 37
Divergent effectiveness of multispecies probiotic preparations on intestinal microbiota structure depends on metabolic properties 37
Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis 37
Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders 37
Pregnane-X-receptor mediates the anti-inflammatoryactivities of rifaximin on detoxification pathways in intestinal epithelialcells. 36
Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction 36
Instruction of Intestinal Microbiota by VSL#3 Reverses NASH and Accelerated Atherosclerosis Caused by Intestinal Inflammation in ApoE(-/-) Mice 35
Targeting FXR in cholestasis: hype or hope. 35
Immunomodulatory functions of FXR 35
Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain. 34
In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygease inhibitors. 34
Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation 34
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH) 34
Bile acids and their receptors in metabolic disorders 34
Bile Acids Activated Receptors in Inflammatory Bowel Disease 34
The identification of farnesoid X receptor modulators as treatment options for non-alcoholic fatty liver disease 34
GPBAR1 (TGR5) LIGATION PROTECTS AGAINST COLITIS DEVELOPMENT BY REGULATING LEUKOCYTE TRAFFINKING AND PROMOTING A IL-10 DEPENDENT SHIFT IN THE M1/M2 PHENOTYPE 33
VARIABILITY IN INDUSTRIAL PRODUCTION AFFECTS PROBIOTICS ACTIVITY: IDENTIFICATION OF BATCHES OF PROBIOTIC VSL#3 THAT INCREASES INTESTINAL PERMEABILITY AND WORSENS COLITIS IN RODENTS 32
Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation 32
Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling 32
COXIBs, CINODs and H₂S-releasing NSAIDs: currentperspectives in the development of safer non steroidal anti-inflammatory drugs 31
GPBAR1 (TGR5) AGONISM REVERSES ENDOTHELIAL DYSFUNCTION AND LIVER INJURY IN A DIETETIC MODEL OF STEATOHEPATITIS 31
Tu1748 - Probiotics Beyond Taxonomy: Evidence that Anti-inflammatory Properties of Live Biotherapeutic Products Require Phenotypic Characterization 31
Bile Acid Signaling in Inflammatory Bowel Diseases 31
GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis 30
The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma 28
Role of Nuclear Receptors in Lipid Dysfunction and Obesity-related Diseases. 28
The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy 28
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma 27
The Bile Acid Receptor TGR5 Maintains Gastrointestinal Homeostasis and Its Activation Rescues From Gastrointestinal Injury Caused by ASA and NSAIDs 27
Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis 27
Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. 26
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH 25
Solomonsterol A, a marine pregnane-X-receptor agonist, attenuates inflammation and immune dysfunction in a mouse model of arthritis. 25
Future trends in the treatment of non-alcoholic steatohepatitis 25
Chenodeoxycholic Acid: An Update on Its Therapeutic Applications 25
Farnesoid X receptor modulators 2014-present: a patent review 25
VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation. 24
Endocrine activities and adipogenic effects of bisphenol AF and its main metabolite 24
Special FX: Harnessing the Farnesoid-X-Receptor to Control Bile Acid Synthesis 24
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma 23
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. 23
Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders 23
Modification of Intestinal Microbiota by VSL#3 Protects Against Development of Pain in the Neonatal Maternal Separation Model. a Whole Genome Array Investigation 22
Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases 22
The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation 22
GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation 22
Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis 22
Organoids as ex vivo culture system to investigate infection-host interaction in gastric pre-carcinogenesis 21
New brominated flame retardants and their metabolites as activators of the pregnane X receptor 20
Mesenchymal cells for skeletal tissue engineering 20
Totale 4.022
Categoria #
all - tutte 17.473
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.473


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201962 0 0 0 0 0 0 0 0 0 7 47 8
2019/2020306 21 16 29 3 36 24 41 11 35 53 15 22
2020/2021673 8 40 26 51 208 29 36 15 45 18 36 161
2021/2022785 10 156 9 21 27 12 20 241 9 35 106 139
2022/20231.677 118 323 13 161 143 156 0 100 588 1 57 17
2023/2024430 40 76 27 15 15 4 157 45 42 9 0 0
Totale 4.171